Your browser doesn't support javascript.
loading
Repurposing sarecycline for osteoinductive therapies: an in vitro and ex vivo assessment.
Martin, Victor; Grenho, Liliana; Fernandes, Maria H; Gomes, Pedro S.
Afiliación
  • Martin V; LAQV/REQUIMTE, U. Porto, 4160-007, Porto, Portugal.
  • Grenho L; BoneLab - Laboratory for Bone Metabolism and Regeneration - Faculty of Dental Medicine, U. Porto, Rua Dr. Manuel Pereira da Silva, 4200-393, Porto, Portugal.
  • Fernandes MH; LAQV/REQUIMTE, U. Porto, 4160-007, Porto, Portugal.
  • Gomes PS; BoneLab - Laboratory for Bone Metabolism and Regeneration - Faculty of Dental Medicine, U. Porto, Rua Dr. Manuel Pereira da Silva, 4200-393, Porto, Portugal.
J Bone Miner Metab ; 41(4): 431-442, 2023 Jul.
Article en En | MEDLINE | ID: mdl-37036531
ABSTRACT

INTRODUCTION:

Tetracyclines (TCs) embrace a class of broad-spectrum antibiotics with unrelated effects at sub-antimicrobial levels, including an effective anti-inflammatory activity and stimulation of osteogenesis, allowing their repurposing for different clinical applications. Recently, sarecycline (SA)-a new-generation molecule with a narrower antimicrobial spectrum-was clinically approved due to its anti-inflammatory profile and reduced adverse effects verified with prolonged use. Notwithstanding, little is known about its osteogenic potential, previously verified for early generation TCs. MATERIALS AND

METHODS:

Accordingly, the present study is focused on the assessment of the response of human bone marrow-derived mesenchymal stromal cells (hBMSCs) to a concentration range of SA, addressing the metabolic activity, morphology and osteoblastic differentiation capability, further detailing the modulation of Wnt, Hedgehog, and Notch signaling pathways. In addition, an ex vivo organotypic bone development system was established in the presence of SA and characterized by microtomographic and histochemical analysis.

RESULTS:

hBMSCs cultured with SA presented a significantly increased metabolic activity compared to control, with an indistinguishable cell morphology. Moreover, RUNX2 expression was upregulated 2.5-fold, and ALP expression was increased around sevenfold in the presence of SA. Further, GLI2 expression was significantly upregulated, while HEY1 and HNF1A were downregulated, substantiating Hedgehog and Notch signaling pathways' modulation. The ex vivo model developed in the presence of SA presented a significantly enhanced collagen deposition, extended migration areas of osteogenesis, and an increased bone mineral content, substantiating an increased osteogenic development.

CONCLUSION:

Summarizing, SA is a promising candidate for drug repurposing within therapies envisaging the enhancement of bone healing/regeneration.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Reposicionamiento de Medicamentos / Erizos Límite: Animals / Humans Idioma: En Revista: J Bone Miner Metab Asunto de la revista: METABOLISMO Año: 2023 Tipo del documento: Article País de afiliación: Portugal

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Reposicionamiento de Medicamentos / Erizos Límite: Animals / Humans Idioma: En Revista: J Bone Miner Metab Asunto de la revista: METABOLISMO Año: 2023 Tipo del documento: Article País de afiliación: Portugal